- Details
- Ashley Ross is joined by Daniel Spratt presenting a European Association of Urology publication on A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer . In a field of rapidly acquiring data, among the challenges that motivated this systematic review was the breadth of papers and data being published. Dr. Spratt and colleagues sought to acquire the most up-to-...
|
- Details
- The Canary Prostate Active Surveillance Study (PASS) is a multi-center research study for men who have chosen active surveillance to manage their prostate cancer. Canary is the world’s only non-profit focused solely on early cancer detection. Active surveillance in PASS means closely monitoring men with prostate cancer and offering treatment if test results show the cancer is getting worse. This i...
|
- Details
- Brian Chapin, MD, joins Matthew Cooperberg, MD, MPH, FACS, in conversation discussing conceiving and executing large phase III trials focused on the management of localized prostate cancer. Dr. Chapin highlights what it takes to get one of these trials off the ground and what the future of trials looks like for men with localized disease. He specifically highlights the actively recruiting Phase II...
|
- Details
- Historically called Gleason 6, and more recently referred to as Grade Group 1, is a term that started in the 1960s with Don Gleason's original description. It was more universally adopted by the late 1980s, and the Grade Group system was initiated in 2014. In this conversation with Matthew Cooperberg, MD, MPH, FACS, Scott Eggener, MD offers his perspective on the importance of understanding Gleaso...
|
- Details
- Christopher Sweeney, MD, sits down with Alicia Morgans, MD, MPH to discuss “DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Prostate Cancer,” a phase 3, 1100 patient study lead by the ANZUP group which randomizes men with high-risk prostate cancer to darolutamide or standard of care. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical Scho...
|
- Details
- Rana McKay joins Alicia Morgans to discuss the outcomes of a study investigating randomized patients with high-risk prostate cancer (Gleason ≥4+3, PSA >20, T3 disease, and lymph nodes <20 mm) to either abiraterone + prednisone + apalutamide + leuprolide (APAL) or abiraterone + prednisone + leuprolide (APL) for a total of 6 cycles (each cycle 28 days), followed by radical prostatectomy. A total of...
|
- Details
- Matt Cooperberg hosts a discussion with Peter Carroll and Laurence Klotz examining their roles in the progress of active surveillance for low-risk prostate cancer and how they incorporate this treatment into clinical practice. They discuss the change in the field from over-detection and overtreatment where radiation and surgery were the primary treatment options to the evolution of active surveill...
|
- Details
- Peter Albers discusses his study of baseline PSA screening of young men across the nation of Germany. The study consists of 45-year-old men who are randomized in two cohorts, one group gets a PSA immediately and the other cohort has a delay of five years. The initial PSA value determines the patient’s risk-adapted strategy and dictates the schedule of further testing. Dr. Albers states that the tr...
|
- Details
- Sigrid Carlsson joins Charles Ryan discussing the epidemiologic outcomes of men in the current era who are facing active surveillance. She reviews the long term data learned from the Memorial Sloan Kettering Cancer Center Experience which mirrors prior reports with low rates of metastasis or cancer-related deaths for patients on active surveillance. They also discuss the migration of pushing the e...
|
- Details
- Matthew Cooperberg discusses active surveillance as the standard of care for men with low-risk prostate cancer as well as data from multiple registries including CaPSURE, MUSIC, AQUA, and SEER, which report increasing rates of active surveillance in men with low-risk disease. He further discusses the factors that may be driving lower uptake of active surveillance in some practices. Biographies: Ma...
|
